HLA-DR10 antigen

Also Known As:

HLA-DR10

Networked: 18 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR10 antigen: 18
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR10 antigen: 18
  - Membrane Proteins: 10078
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR10 antigen: 18
Biological Factors: 2472
- Antigens: 143924
  - Surface Antigens: 5813
    - Histocompatibility Antigens: 1132
      - HLA Antigens: 8934
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR10 antigen: 18
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR10 antigen: 18
  - Isoantigens: 1221
    - Histocompatibility Antigens: 1132
      - HLA Antigens: 8934
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR10 antigen: 18
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR10 antigen: 18

Experts

1.	Hok, Saphon: 6 articles (10/2010 - 05/2007)
2.	Balhorn, Rod: 6 articles (04/2009 - 01/2005)
3.	DeNardo, Sally J: 5 articles (12/2008 - 05/2007)
4.	Corzett, Michele: 4 articles (04/2009 - 08/2007)
5.	Natarajan, Arutselvan: 4 articles (04/2009 - 05/2007)
6.	DeNardo, Gerald L: 4 articles (12/2008 - 05/2007)
7.	Cosman, Monique: 4 articles (10/2007 - 01/2005)
8.	Mirick, Gary: 3 articles (04/2009 - 09/2007)
9.	Perkins, Julie: 3 articles (10/2007 - 05/2007)
10.	Lehmann, Joerg: 2 articles (12/2008 - 10/2007)

Related Diseases

1.	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/01/2007 - "Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma." 09/15/2007 - "Lym-1 antibody, which binds selectively to HLA-DR10 on malignant B-cell lymphocytes, has proved to be effective in delivering radionuclides to non-Hodgkin's lymphoma and leukemia. " 05/01/2007 - "Selective high-affinity ligands (SHALs) were synthesized as molecular targeting agents for HLA-DR10, a cell surface receptor upregulated on malignant B-cell lymphocytes in non-Hodgkin's lymphoma and leukemia. " 01/01/2005 - "Our NMR laboratory is involved in the identification of small molecules, or ligands, that bind to target protein receptors such as tetanus neurotoxin (TeNT) and botulinum neurotoxin, anthrax proteins, and HLA-DR10 receptors on non-Hodgkin lymphoma cancer cells. "
2.	Leukemia 09/15/2007 - "Lym-1 antibody, which binds selectively to HLA-DR10 on malignant B-cell lymphocytes, has proved to be effective in delivering radionuclides to non-Hodgkin's lymphoma and leukemia. " 05/01/2007 - "Selective high-affinity ligands (SHALs) were synthesized as molecular targeting agents for HLA-DR10, a cell surface receptor upregulated on malignant B-cell lymphocytes in non-Hodgkin's lymphoma and leukemia. "
3.	Echinococcosis (Hydatid Cysts) 12/01/2012 - "The results proved that HLA-DR16 and HLA-DR7 alleles were the suitable markers of susceptibility association while HLA-DR1 and HLA-DR10 alleles might confer protection against hydatidosis. "
4.	Lymphoma (Lymphomas) 12/01/2008 - "Using cell-binding and death assays and confocal microscopy, SHAL uptake, residualization, and cytocidal activity were evaluated in HLA-DR10 expressing and nonexpressing live, human lymphoma cell lines. " 08/01/2007 - "Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules." 06/01/2007 - "This antibody, which recognizes the HLA-DR10 antigen preferentially expressed in B-cell lymphomas, was recently shown to induce apoptosis upon binding to lymphoma cells. " 09/01/1996 - "Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10."
5.	Rheumatoid Arthritis 01/01/2000 - "Most patients with rheumatoid arthritis (RA) express HLA-DR4, HLA-DR1 or HLA-DR10. " 01/01/1997 - "Most patients with rheumatoid arthritis (RA) express HLA-DR4, HLA-DR1, or HLA-DR10. " 03/01/1996 - "HLA-DR4 and HLA-DR10 motifs that carry susceptibility to rheumatoid arthritis bind 70-kD heat shock proteins." 06/01/2008 - "The rheumatoid arthritis-associated allele HLA-DR10 (DRB11001) shares part of its repertoire with HLA-DR1 (DRB10101) and HLA-DR4 (DRB*0401)."

Related Drugs and Biologics

1.	HLA-DR1 Antigen (HLA DR1 Antigen)
2.	HLA-DR7 Antigen (HLA DR7 Antigen)
3.	Radioisotopes (Radionuclides)
4.	HLA-DR16 antigen
5.	HLA-DR4 Antigen (HLA DR4 Antigen)
6.	Ligands
7.	Peptides (Polypeptides)
8.	Epitopes
9.	Cell Surface Receptors
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Immunotherapy